快速简易检测念珠菌血症试验第2部分(DIRECT2):T2Candida panel的前瞻性多中心研究
在14个中心纳入152例念珠菌血症患者,比较T2Candida与同步血培养的阳性率。T2Candida阳性率45%(69/152)高于同步血培养24%(36/152),P<.0001;T2Candida临床敏感性89%(32/36)。结论认为T2Candida在血培养阳性时诊断念珠菌血症敏感,抗真菌治疗期间可检出同步血培养漏检的血流感染。
要点
- T2Candida阳性率45%(69/152)高于同步血培养24%(36/152),P<.0001。
- T2Candida临床敏感性89%,36例同步血培养阳性中32例T2Candida阳性。
- 既往抗真菌治疗、中性粒细胞减少和白色念珠菌血症与T2Candida阳性独立相关(P<.05)。
核心结论
- T2Candida在血培养阳性时诊断念珠菌血症敏感。
- 在接受抗真菌治疗的患者中,T2Candida检出了同步血培养漏检的血流感染。
- T2Candida可能通过缩短念珠菌检出和菌种鉴定时间改善诊疗,在抗真菌治疗期间保持敏感性,且结果阴性时活动性念珠菌血症可能性低。
研究设计与样本
- 前瞻性多中心研究,在14个中心通过诊断性血培养(dBC)识别白色念珠菌、光滑念珠菌、近平滑念珠菌、热带念珠菌或克柔念珠菌念珠菌血症患者。
- 同步采集随访血样本用于T2Candida和同步培养(cBC)检测。
- T2Candida结果按白色念珠菌/热带念珠菌、光滑念珠菌/克柔念珠菌和近平滑念珠菌定性报告。
- 共纳入152例患者。
主要发现
- 诊断性血培养与T2Candida/cBC样本采集之间的中位时间为55.5小时(范围16.4-148.4)。
- T2Candida和cBC阳性率分别为45%(69/152)和24%(36/152),P<.0001。
- T2Candida临床敏感性为89%,36例cBC阳性患者中32例T2Candida阳性。
- 联合检测结果:T2+/cBC+为21%(32/152);T2+/cBC-为24%(37/152);T2-/cBC+为3%(4/152);T2-/cBC-为52%(79/152)。
- 既往抗真菌治疗、中性粒细胞减少和白色念珠菌血症与T2Candida阳性及T2+/cBC-结果独立相关(P值<.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Blood cultures are approximately 50% sensitive for diagnosing invasive candidiasis. The T2Candida nanodiagnostic panel uses T2 magnetic resonance and a dedicated instrument to detect Candida directly within whole blood samples. METHODS: Patients with Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, or Candida krusei candidemia were identified at 14 centers using diagnostic blood cultures (dBCs). Follow-up blood samples were collected concurrently for testing by T2Candida and companion cultures (cBCs). T2Candida results are reported qualitatively for C. albicans/C. tropicalis, C. glabrata/C. krusei, and C. parapsilosis. T2Candida and cBCs were positive if they detected a species present in the dBC. RESULTS: Median time between collection of dBC and T2Candida/cBC samples in 152 patients was 55.5 hours (range, 16.4-148.4). T2Candida and cBCs were positive in 45% (69/152) and 24% (36/152) of patients, respectively (P < .0001). T2Candida clinical sensitivity was 89%, as positive results were obtained in 32/36 patients with positive cBCs. Combined test results were both positive (T2+/cBC+), 21% (32/152); T2+/cBC-, 24% (37/152); T2-/cBC+, 3% (4/152); and T2-/cBC-, 52% (79/152). Prior antifungal therapy, neutropenia, and C. albicans candidemia were independently associated with T2Candida positivity and T2+/cBC- results (P values < .05). CONCLUSIONS: T2Candida was sensitive for diagnosing candidemia at the time of positive blood cultures. In patients receiving antifungal therapy, T2Candida identified bloodstream infections that were missed by cBCs. T2Candida may improve care by shortening times to Candida detection and species identification compared to blood cultures, retaining sensitivity during antifungal therapy and rendering active candidemia unlikely if results are negative. CLINICAL TRIALS REGISTRATION: NCT01525095.
引用
- Clancy CJ, Pappas PG, Vazquez J, et al. Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clin Infect Dis. 2018. PMID: 29438475. doi:10.1093/cid/cix1095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。